News | Radiopharmaceuticals and Tracers | July 07, 2016

Cell>Point Executes China License for Oncardia Diagnostic Imaging Agent

Agreement with United Eastern Pharmaceutical brings agent for cancer and heart disease imaging to China, Hong Kong and Macau

Cell>Point, license agreement, China, United Eastern Pharmaceutical, Oncardia imaging agent

July 7, 2016 — Cell>Point announced in mid-June it has entered into an exclusive license agreement for China, Hong Kong and Macau with United Eastern Pharmaceutical (UEP), a company representing a consortium from the United States and China. The license agreement covers Cell>Point’s diagnostic radiopharmaceutical Oncardia (ethylenedicysteine-glucosamine) which was developed for labeling with technetium-99m for single photon emission computed tomography (SPECT) cameras or 68-gallium for positron emission tomography (PET) cameras for imaging in cancer and cardiovascular disease.

Oncardia is based on an ethylenedicysteine drug conjugate platform licensed by Cell>Point from The University of Texas MD Anderson Cancer Center. The license with UEP provides for Cell>Point to receive an upfront payment and regulatory milestone payments as well as royalties on sales. Cell>Point will be seeking regulatory approval from the China Food and Drug Administration (FDA) to expand its Phase 3 lung cancer imaging trial to include clinical sites in China. The parties have agreed that when the current cardiovascular study reaches Phase 3, Cell>Point will include China clinical sites as part of the study.

According to Haoran Xi, CEO of UEP, “China needs affordable and accessible diagnostic molecular imaging to reach a substantially larger universe of people than is presently the case with the current standard of care. Plans are to pursue approvals in diagnosing and staging lung, head and neck, colorectal, breast, liver, stomach, lymphoma and other cancers in addition to diagnosing the presence and extent of cardiac ischemia. Oncardia can be used to assess the patient’s response to therapy while undergoing therapy. This will give oncologists a valuable tool to determine if the patient is benefiting from the selected therapy or should the oncologist reconsider the choice of therapy. The Chinese Central Government is implementing programs to improve the quality of medical care throughout the country. Cancer and vascular disease are the leading causes of death in China.”

Oncardia was developed to address the limitations of FDG-PET (positron emission tomography) in cancer imaging while increasing access to cancer imaging to a significantly greater number of hospitals worldwide. Cell>Point is completing a Phase 3 trial for Oncardia in lung cancer under a Letter of Agreement with the FDA pursuant to a Special Protocol Assessment, and a Phase 2b cardiovascular trial in patients with coronary artery disease. The focus in cardiology is to assess the patient’s ischemia in a rest-only imaging procedure which will dramatically shorten the time required to complete the patient’s study and achieve noticeably greater diagnostic accuracy compared to the standard of care.

For more information: www.cellpointweb.com

Related Content

Videos | Radiology Business | March 22, 2019
American Society of Radiologic Technologists (ASRT) President Melissa Jackowski, Ed.D., R.T.(R)(M), FASRT, explains e
NIH Study of Brain Energy Patterns Provides New Insights into Alcohol Effects

NIH scientists present a new method for combining measures of brain activity (left) and glucose consumption (right) to study regional specialization and to better understand the effects of alcohol on the human brain. Image courtesy of Ehsan Shokri-Kojori, Ph.D., of NIAAA.

News | Neuro Imaging | March 22, 2019
March 22, 2019 — Assessing the patterns of energy use and neuronal activity simultaneously in the human brain improve
ASRT Elects Four New Officers for 2019
News | Radiology Business | March 22, 2019
March 22, 2019 — Members of the Americ...
Improving Molecular Imaging Using a Deep Learning Approach
News | Nuclear Imaging | March 21, 2019
Generating comprehensive molecular images of organs and tumors in living organisms can be performed at ultra-fast speed...
PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy
News | PET Imaging | March 18, 2019
A new study positron emission tomography (PET) scans has identified a biomarker that may accurately predict which...
Researchers Create New Method for Developing Cancer Imaging Isotopes

Prototype fluidic system for zirconium-89 purification. Image taken through a hot cell window at the Department of Radiology, University of Washington. Image courtesy of Matthew O’Hara, Pacific Northwest National Laboratory

News | Radiopharmaceuticals and Tracers | March 14, 2019
A team of researchers at the University of Washington announced they developed a new automated system for producing...
Imaging Technology News Named 2019 Regional and National Azbee Awards Finalist
News | Radiology Business | March 08, 2019
March 8, 2019 — Imaging Technology News (ITN) was named a finalist in multiple categories across pr
Podcast | Cardiac Imaging | March 08, 2019
Why CT angiography cannot replace invasive angiography